Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the

Grace A Chappell1, Julia E Rager2, Jeffrey Wolf3

  • 1ToxStrategies, Inc, Asheville, NC, USA.

Toxicologic Pathology
|September 28, 2019
PubMed

Insights

Hexavalent chromium (Cr(VI)), captan, and folpet induce similar molecular and cellular changes in mouse intestines, suggesting a shared pathway for intestinal carcinogenesis. These findings aid in developing adverse outcome pathways for intestinal cancer.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Carcinogenesis

Background:

  • Small intestine carcinogenesis is rare in humans and rodents.
  • Hexavalent chromium (Cr(VI)), captan, and folpet are known to induce intestinal carcinogenesis in mice.
  • Previous studies showed similar histopathological responses in mice exposed to these agents.

Purpose of the Study:

  • To analyze the transcriptomic responses to Cr(VI), captan, and folpet exposure in mouse duodenum.
  • To identify common molecular mechanisms underlying intestinal carcinogenesis induced by these agents.
  • To inform the development of an adverse outcome pathway for intestinal cancer.

Main Methods:

  • TempO-Seq technology was used to analyze transcriptomic responses.
  • Formalin-fixed, paraffin-embedded duodenal sections from mice exposed to Cr(VI), captan, or folpet were analyzed.
  • Gene expression data was compared to identify differentially expressed genes and pathways.

Main Results:

  • Transcriptional responses were similar across all three agents.
  • 126/546 (23%) differentially expressed genes were altered in the same direction.
  • 25 pathways were upregulated, including those related to cellular metabolism, stress, inflammation, cell proliferation, hypoxia-inducible factor 1 (HIF-1), and activator protein 1 (AP1) signaling.

Conclusions:

  • Cr(VI), captan, and folpet induce similar molecular, cellular, and tissue-level changes in the mouse duodenum.
  • The identified molecular changes are linked to intestinal injury, angiogenesis, and carcinogenesis.
  • These findings support the development of a shared adverse outcome pathway for intestinal cancer.